OncLive, the leading digital provider of resources and information to oncology professionals, surpassed 713,777-page views on Onclive.com for the month of October, announced Michael J. Hennessy Jr., president of MJH Associates, parent company of OncLive.
We are thrilled to reach 700K page views for the month October, said Hennessy. This is another major milestone for OncLive, and we wouldnt be able to be the go-to resource for oncology professionals without our incredible team.
During the month of October, the top-performing articles that helped OncLive.com reach these page views included:
- Oncolytic Virus Explored in Advanced HCC
- Olaparib Substantially Improves PFS as Frontline Maintenance in Ovarian Cancer
- Olaparib Substantially Improves PFS as Frontline Maintenance in Ovarian CancerFDA Approves Talazoparib for BRCA-Mutated, HER2-Negative Breast Cancer
Reaching a new monthly web traffic record really shows that OncLive is consistently growing to be the best of the best, said Robert Goldsmith, vice president of OncLive. We are so honored that we are able to provide clinicians with the resources they need in order to provide the best patient care.
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
A digital platform of resources for practicing oncologists, OncLive offers oncology professionals information they can use to help provide the best patient care. OncLive.com is the official website for the MJH Associates Inc. Oncology Specialty Group, which publishes OncologyLive, Oncology Nursing News and more. MJH Associates Inc. is a full-service health care communications company offering education, research and medical media, including curetoday.com and CURE magazine, the largest U.S. consumer publication focused entirely on cancer. Combining science and humanity to make cancer understandable, CURE reaches patients, cancer centers and advocacy groups.